Search Results
Showing Results for Jean-Frederic Colombel
The U-EXCEL (NCT03345849) and U-EXCEED (NCT03345836) phase 3 studies investigated the efficacy and safety of upadacitinib, an oral, selective JAK inhibitor in patients with moderate-to-severe Crohn’s disease. touchIMMUNOLOGY were delighted to speak with Dr. Jean-Frederic Colombel (Icahn School of Medicine, ...
LIBERTY-CD (ClinicalTrials.gov Identifier: NCT03945019) is a phase 3 study investigating the efficacy and safety of subcutaneous infliximab as maintenance therapy in moderately to severely active Crohn's disease. In this touchIMMUNOLOGY interview we spoke with Dr. Jean-Frederic Colombel (Icahn School of ...
touchIMMUNOLOGY caught up with Prof. Jean-Frederic Colombel (Icahn School of Medicine, Mount Sinai, New York, NY, USA) to discuss the objectives, design and findings from the U-EXCEED phase 3 study, investigating upadacitinib induction therapy in moderate to severe crohn's disease. The ...
touchIMMUNOLOGY caught up with Professor Jean-Frederic Colombel (The Mount Sinai Hospital, NY, USA) to discuss the results from the UPA phase 3 programme, investigating the efficacy of upadacitinib on  the extraintestinal manifestations of ulcerative colitis. The abstract entitled ‘Effect of upadacitinib (...
We were delighted to speak with Jean-Frederic Colombel (Icahn School of Medicine at Mount Sinai, New York, US) around his talk on ‘Overcoming the Plateau in IBD Treatment’ which was presented at the virtual 2021 Crohn’s & Colitis Congress, 21-24 ...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
